PPARγ Activation: A Potential Treatment For Pulmonary Hypertension

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Science Translational Medicine

• Publication date

  2009-12-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.3000267PMID 20371457
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study

  2010cited by this paper
• Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.

  2010cited by this paper
• Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

  2009cited by this paper
• Cellular and molecular basis of pulmonary arterial hypertension.

  2009influential reference
• Inflammation, growth factors, and pulmonary vascular remodeling.

  2009cited by this paper
• Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension

  2009cited by this paper
• A Functional Single-Nucleotide Polymorphism in the TRPC6 Gene Promoter Associated With Idiopathic Pulmonary Arterial Hypertension

  2009cited by this paper
• Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization.

  2009cited by this paper
• Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

  2009cited by this paper
• Interleukin-6 Overexpression Induces Pulmonary Hypertension

  2009cited by this paper
• New Mechanism of Rosiglitazone to Reduce Neointimal Hyperplasia: Activation of Glycogen Synthase Kinase-3&bgr; Followed by Inhibition of MMP-9

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease.

  2009cited by this paper
• Genetics and genomics of pulmonary arterial hypertension.

  2009cited by this paper
• Adiponectin ameliorates hypoxia-induced pulmonary arterial remodeling.

  2009cited by this paper
• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

  2009cited by this paper
• Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling.

  2009cited by this paper
• Imatinib in Patients with Severe Pulmonary Artery Hypertension (PAH) Refractory to Standard Therapy.

  2009cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature

  2008cited by this paper
• Insulin resistance in pulmonary arterial hypertension

  2008cited by this paper
• Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension

  2008cited by this paper
• Renal and Vascular Mechanisms of Thiazolidinedione-Induced Fluid Retention

  2008cited by this paper
• Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension

  2008cited by this paper
• Experience With Imatinib to Treat Pulmonary Arterial Hypertension

  2008cited by this paper
• Abstract 407: Rapid Effect of Single Dose Rosiglitazone Treatment on Endothelial Function in Healthy Men with Normal Glucose Tolerance: Data from a Randomized, Placebo-Controlled, Double-Blind Study

  2008cited by this paper
• Pioglitazone Inhibits the Expression of Inflammatory Cytokines From Both Monocytes and Lymphocytes in Patients With Impaired Glucose Tolerance

  2008cited by this paper
• An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

  2008cited by this paper
• Pulmonary Arterial Hypertension Is Linked to Insulin Resistance and Reversed by Peroxisome Proliferator–Activated Receptor-&ggr; Activation

  2007cited by this paper
• Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial.

  2007cited by this paper
• Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension.

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

  2007cited by this paper
• Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.

  2007cited by this paper
• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Data and safety monitoring of rosiglitazone trials.

  2007cited by this paper
• Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease

  2006cited by this paper
• Adiponectin Acts as an Endogenous Antithrombotic Factor

  2006cited by this paper
• Activation of Peroxisome Proliferator-Activated Receptor &ggr; Suppresses Telomerase Activity in Vascular Smooth Muscle Cells

  2006cited by this paper
• Epidermal Growth Factor Receptor Blockade Mediates Smooth Muscle Cell Apoptosis and Improves Survival in Rats With Pulmonary Hypertension

  2005cited by this paper
• PPARγ-mediated insulin sensitization: the importance of fat versus muscle

  2005cited by this paper
• Adiponectin Inhibits Cell Proliferation by Interacting with Several Growth Factors in an Oligomerization-dependent Manner*

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats

  2005cited by this paper
• "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.

  2005cited by this paper
• Pioglitazone improves left ventricular diastolic function in patients with essential hypertension.

  2005cited by this paper
• Pioglitazone initiation and subsequent hospitalization for congestive heart failure

  2005cited by this paper
• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  2005cited by this paper
• Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension

  2005cited by this paper
• PPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Ligands Inhibit Rho/Rho Kinase Pathway by Inducing Protein Tyrosine Phosphatase SHP-2

  2004cited by this paper
• C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link Between C-Reactive Protein and Cardiovascular Disease

  2004cited by this paper
• Adipocyte Low Density Lipoprotein Receptor-related Protein Gene Expression and Function Is Regulated by Peroxisome Proliferator-activated Receptor γ*

  2003cited by this paper
• LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis

  2003influential reference
• Peroxisome Proliferator-Activated Receptor Gamma (PPAR&ggr;) Expression Is Decreased in Pulmonary Hypertension and Affects Endothelial Cell Growth

  2003cited by this paper
• 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma.

  2002cited by this paper
• Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats.

  2002cited by this paper
• Vascular Inflammation Is Negatively Autoregulated by Interaction Between CCAAT/Enhancer-Binding Protein-&dgr; and Peroxisome Proliferator-Activated Receptor-&ggr;

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase Cδ Pathway in Vascular Smooth Muscle Cells*

  2001cited by this paper
• Peroxisome proliferator-activated receptor-γ ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in Vascular smooth muscle cell migration

  2001cited by this paper
• Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension: A Gene Microarray Analysis

  2001cited by this paper
• Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells*

  2000cited by this paper
• Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor

  2000cited by this paper
• Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.

  2000cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells.

  2000cited by this paper
• Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway.

  1999cited by this paper
• Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ

  1996cited by this paper
• Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow.

  1995cited by this paper
• Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.

  1995cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• Journal of Neuroinflammation Interleukin-1β and Anaphylatoxins Exert a Synergistic Effect on Ngf Expression by Astrocytes

  year unknowncited by this paper

• Echinatin Alleviates Experimental Pulmonary Hypertension by PPARγ Pathway Activation

  2026cites this paper
• Calycosin ameliorates high-altitude pulmonary edema by regulating macrophage polarization through the PPAR-γ/NF-κB pathway: a comprehensive analysis of network pharmacology, molecular docking, and experimental validation.

  2026cites this paper
• Nuclear receptors in pulmonary hypertension: From pathophysiological mechanisms to clinical implications.

  2025cites this paper
• Pulmonary hypertension and insulin resistance: a mechanistic overview

  2024cites this paper
• Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation.

  2024cites this paper
• Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function

  2024cites this paper
• SMYD2-Methylated PPARγ Facilitates Hypoxia-Induced Pulmonary Hypertension by Activating Mitophagy

  2024cites this paper
• Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential

  2023cites this paper
• Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension

  2022cites this paper
• Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension

  2021cites this paper
• Promising therapeutic approaches in pulmonary arterial hypertension.

  2021cites this paper
• FGF21 attenuates hypoxia-induced dysfunction and inflammation in HPAECs via the microRNA-27b-mediated PPARγ pathway

  2021cites this paper
• Adipokines and Metabolic Regulators in Human and Experimental Pulmonary Arterial Hypertension

  2021cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2021cites this paper
• Prognostic significance of insulin resistance in pulmonary hypertension

  2021cites this paper
• The role of mitochondrial reactive oxygen species in oxygen sensing in the pulmonary vasculature – use of novel genetic tools

  2021cites this paper
• PPARγ and TGFβ—Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys

  2021cites this paper
• Exploring the mechanism of the anti-hypertension properties of Morinda citrifolia through a bioinformatics approach

  2021cites this paper
• Low-intensity pulsed ultrasound prevents angiotensin II-induced aortic smooth muscle cell phenotypic switch via hampering miR-17-5p and enhancing PPAR-γ.

  2021cites this paper
• The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

  2021cites this paper
• Pulmonary Hypertension in Obese Mice Is Accompanied by a Reduction in PPAR-γ Expression in Pulmonary Artery

  2021cites this paper
• Altered metabolism in pulmonary hypertension: fuelling the fire or just smoke?

  2020cites this paper
• Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine

  2020cites this paper
• Vascular Metabolic Mechanisms of Pulmonary Hypertension

  2020cites this paper
• Activation of The Metabolic Master Regulator PPARγ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

  2020cites this paper
• Grape seed procyanidin suppresses inflammation in cigarette smoke-exposed pulmonary arterial hypertension rats by the PPAR-γ/COX-2 pathway.

  2019cites this paper
• Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling.

  2019cites this paper
• Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension

  2019cites this paper
• Pulmonary Hypertension and Obesity: Focus on Adiponectin

  2019cites this paper
• Pulmonary arterial remodelling by deficiency of peroxisome proliferator-activated receptor-γ in murine vascular smooth muscle cells occurs independently of obesity-related pulmonary hypertension

  2019cites this paper
• The Search for Disease-Modifying Therapies in Pulmonary Hypertension

  2019cites this paper
• Role of RASEF hypermethylation in cigarette smoke-induced pulmonary arterial smooth muscle remodeling

  2019cites this paper
• PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.

  2019cites this paper
• Pulmonary Circulation in Obesity, Diabetes, and Metabolic Syndrome.

  2019cites this paper
• Fibroblast growth factor 21 attenuates hypoxia-induced pulmonary hypertension by upregulating PPARγ expression and suppressing inflammatory cytokine levels.

  2018cites this paper
• Long noncoding RNA SRA1 attenuates hypoxia-induced injury in H9c2 cardiomyocytes through regulating PPARγ/NF-κB signaling pathway.

  2018cites this paper
• Repurposing rosiglitazone, a PPAR‐&ggr; agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH

  2018cites this paper
• PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation

  2018cites this paper
• Prenatal treatment with rosiglitazone attenuates vascular remodeling and pulmonary monocyte influx in experimental congenital diaphragmatic hernia

  2018cites this paper
• PPARγ Alleviates Right Ventricular Failure Secondary to Pulmonary Arterial Hypertension in Rats.

  2017cites this paper
• Role of Transcription Factors in Pulmonary Artery Smooth Muscle Cells: An Important Link to Hypoxic Pulmonary Hypertension.

  2017cites this paper
• The Myofibroblast: TGFβ-1, A Conductor which Plays a Key Role in Fibrosis by Regulating the Balance between PPARγ and the Canonical WNT Pathway

  2017influential citation
• Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice

  2017cites this paper
• PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism.

  2017cites this paper
• A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma.

  2016cites this paper
• Pulmonary Hypertension in Patients with Heart Failure and Preserved Ejection Fraction: Differential Diagnosis and Management

  2016cites this paper
• Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure.

  2015cites this paper
• Impaired Right Ventricular Hemodynamics Indicate Preclinical Pulmonary Hypertension in Patients With Metabolic Syndrome

  2015cites this paper
• Metabolic Dysfunction in Pulmonary Arterial Hypertension

  2015cites this paper
• Impact of Diabetes in Patients with Pulmonary Hypertension

  2015cites this paper
• Pulmonary Arterial Hypertension and Insulin Resistance

  2014cites this paper
• Idiopathic Pulmonary Arterial Hypertension in the Pediatric Age Group

  2014cites this paper
• The MicroRNA-130/301 Family Controls Vasoconstriction in Pulmonary Hypertension*

  2014cites this paper
• Rosiglitazone Attenuated Endothelin-1-Induced Vasoconstriction of Pulmonary Arteries in the Rat Model of Pulmonary Arterial Hypertension via Differential Regulation of ET-1 Receptors

  2014cites this paper
• The metabolic basis of pulmonary arterial hypertension.

  2014cites this paper
• The Metabolic Theory of Pulmonary Arterial Hypertension

  2014cites this paper
• Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.

  2014cites this paper
• Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.

  2014cites this paper
• Molecular Bases of Disease

  2013cites this paper
• Attenuating Endoplasmic Reticulum Stress as a Novel Therapeutic Strategy in Pulmonary Hypertension

  2013cites this paper
• Interdisciplinary Networks for the Treatment of Childhood Pulmonary Vascular Disease: What Pulmonary Hypertension Doctors Can Learn from Pediatric Oncologists

  2013cites this paper
• Hyperoxia synergizes with mutant bone morphogenic protein receptor 2 to cause metabolic stress, oxidant injury, and pulmonary hypertension.

  2013cites this paper
• Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction.

  2013cites this paper
• Reactive oxygen and nitrogen species in pulmonary hypertension.

  2012cites this paper
• Peroxisome Proliferator-Activated Receptor-&ggr; Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2B Receptor

  2012cites this paper
• Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis

  2012cites this paper
• A process-based review of mouse models of pulmonary hypertension

  2012cites this paper
• Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models.

  2012cites this paper
• New perspectives for the treatment of pulmonary hypertension

  2011cites this paper
• Pediatric pulmonary arterial hypertension: current and emerging therapeutic options

  2011cites this paper
• Hypoxia induces downregulation of PPAR-γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-β signaling.

  2011cites this paper
• Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension

  2011cites this paper
• Fenfluramine-induced gene dysregulation in human pulmonary artery smooth muscle and endothelial cells

  2011cites this paper
• Pulmonary arterial hypertension - smooth muscle cell proliferation and perlecan

  2011cites this paper
• Fatty Acid Oxidation and Malonyl-CoA Decarboxylase in the Vascular Remodeling of Pulmonary Hypertension

  2010cites this paper
• Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis

  2010cites this paper
• Systems-level regulation of microRNA networks by miR-130 / 301 promotes pulmonary hypertension

  year unknowncites this paper
• Peroxisome Proliferator-Activated Receptor-γ Ameliorates Pulmonary Arterial Hypertension by Inhibiting 5-Hydroxytryptamine 2 B Receptor

  year unknowncites this paper
• Systems-level regulation of microRNA networks by miR-130 / 301 promotes pulmonary hypertension

  year unknowncites this paper
• PPARg Links BMP2 and TG Fb1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism

  year unknowninfluential citation